These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 22588883)

  • 1. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.
    Vivanco I; Robins HI; Rohle D; Campos C; Grommes C; Nghiemphu PL; Kubek S; Oldrini B; Chheda MG; Yannuzzi N; Tao H; Zhu S; Iwanami A; Kuga D; Dang J; Pedraza A; Brennan CW; Heguy A; Liau LM; Lieberman F; Yung WK; Gilbert MR; Reardon DA; Drappatz J; Wen PY; Lamborn KR; Chang SM; Prados MD; Fine HA; Horvath S; Wu N; Lassman AB; DeAngelis LM; Yong WH; Kuhn JG; Mischel PS; Mehta MP; Cloughesy TF; Mellinghoff IK
    Cancer Discov; 2012 May; 2(5):458-71. PubMed ID: 22588883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Occupy EGFR.
    Park JH; Lemmon MA
    Cancer Discov; 2012 May; 2(5):398-400. PubMed ID: 22588876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers.
    Barkovich KJ; Hariono S; Garske AL; Zhang J; Blair JA; Fan QW; Shokat KM; Nicolaides T; Weiss WA
    Cancer Discov; 2012 May; 2(5):450-7. PubMed ID: 22588882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients.
    Akhavan D; Pourzia AL; Nourian AA; Williams KJ; Nathanson D; Babic I; Villa GR; Tanaka K; Nael A; Yang H; Dang J; Vinters HV; Yong WH; Flagg M; Tamanoi F; Sasayama T; James CD; Kornblum HI; Cloughesy TF; Cavenee WK; Bensinger SJ; Mischel PS
    Cancer Discov; 2013 May; 3(5):534-47. PubMed ID: 23533263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
    Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
    Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
    Griffero F; Daga A; Marubbi D; Capra MC; Melotti A; Pattarozzi A; Gatti M; Bajetto A; Porcile C; Barbieri F; Favoni RE; Lo Casto M; Zona G; Spaziante R; Florio T; Corte G
    J Biol Chem; 2009 Mar; 284(11):7138-48. PubMed ID: 19147502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and pharmacological inhibition of TrkB and EGFR in glioblastoma.
    Pinheiro KV; Thomaz A; Souza BK; Metcalfe VA; Freire NH; Brunetto AT; de Farias CB; Jaeger M; Bambini V; Smith CGS; Shaw L; Roesler R
    Mol Biol Rep; 2020 Sep; 47(9):6817-6828. PubMed ID: 32862352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
    Tabara K; Kanda R; Sonoda K; Kubo T; Murakami Y; Kawahara A; Azuma K; Abe H; Kage M; Yoshinaga A; Tahira T; Hayashi K; Arao T; Nishio K; Rosell R; Kuwano M; Ono M
    PLoS One; 2012; 7(7):e41017. PubMed ID: 22815900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies.
    Cho J; Pastorino S; Zeng Q; Xu X; Johnson W; Vandenberg S; Verhaak R; Cherniack AD; Watanabe H; Dutt A; Kwon J; Chao YS; Onofrio RC; Chiang D; Yuza Y; Kesari S; Meyerson M
    Cancer Res; 2011 Dec; 71(24):7587-96. PubMed ID: 22001862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
    Tang Z; Jiang S; Du R; Petri ET; El-Telbany A; Chan PS; Kijima T; Dietrich S; Matsui K; Kobayashi M; Sasada S; Okamoto N; Suzuki H; Kawahara K; Iwasaki T; Nakagawa K; Kawase I; Christensen JG; Hirashima T; Halmos B; Salgia R; Boggon TJ; Kern JA; Ma PC
    Oncogene; 2009 Jan; 28(4):518-33. PubMed ID: 19015641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
    Park KS; Raffeld M; Moon YW; Xi L; Bianco C; Pham T; Lee LC; Mitsudomi T; Yatabe Y; Okamoto I; Subramaniam D; Mok T; Rosell R; Luo J; Salomon DS; Wang Y; Giaccone G
    J Clin Invest; 2014 Jul; 124(7):3003-15. PubMed ID: 24911146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
    Greulich H; Chen TH; Feng W; Jänne PA; Alvarez JV; Zappaterra M; Bulmer SE; Frank DA; Hahn WC; Sellers WR; Meyerson M
    PLoS Med; 2005 Nov; 2(11):e313. PubMed ID: 16187797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
    Furuyama K; Harada T; Iwama E; Shiraishi Y; Okamura K; Ijichi K; Fujii A; Ota K; Wang S; Li H; Takayama K; Giaccone G; Nakanishi Y
    Cancer Sci; 2013 May; 104(5):584-9. PubMed ID: 23387505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
    Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
    Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer.
    Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S
    Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors.
    Yuza Y; Glatt KA; Jiang J; Greulich H; Minami Y; Woo MS; Shimamura T; Shapiro G; Lee JC; Ji H; Feng W; Chen TH; Yanagisawa H; Wong KK; Meyerson M
    Cancer Biol Ther; 2007 May; 6(5):661-7. PubMed ID: 17495523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
    Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
    Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant
    Udagawa H; Hasako S; Ohashi A; Fujioka R; Hakozaki Y; Shibuya M; Abe N; Komori T; Haruma T; Terasaka M; Fujita R; Hashimoto A; Funabashi K; Yasuda H; Miyadera K; Goto K; Costa DB; Kobayashi SS
    Mol Cancer Res; 2019 Nov; 17(11):2233-2243. PubMed ID: 31467113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
    Bean J; Brennan C; Shih JY; Riely G; Viale A; Wang L; Chitale D; Motoi N; Szoke J; Broderick S; Balak M; Chang WC; Yu CJ; Gazdar A; Pass H; Rusch V; Gerald W; Huang SF; Yang PC; Miller V; Ladanyi M; Yang CH; Pao W
    Proc Natl Acad Sci U S A; 2007 Dec; 104(52):20932-7. PubMed ID: 18093943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice.
    Zerbe LK; Dwyer-Nield LD; Fritz JM; Redente EF; Shroyer RJ; Conklin E; Kane S; Tucker C; Eckhardt SG; Gustafson DL; Iwata KK; Malkinson AM
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):605-20. PubMed ID: 18030469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.